United States · FDA National Drug Code directory
Ranolazine
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 63304-017_9d320810-99dc-4276-ab06-688b60cc957d
- Product NDC
- 63304-017
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- Ranolazine
- Labeler
- Sun Pharmaceutical Industries, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20190528
- Source listing expiry
- 20261231
Source-listed ingredients
- RANOLAZINE — 500 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-017-05) · 63304-017-05
- 180 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-017-28) · 63304-017-28
- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-017-60) · 63304-017-60
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →